General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

- Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor-β1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (Loma Linda, CA; Winston-Salem, NC, USA)

- IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (Omaha, NE; Ocala, FL, USA)


- Effect of GPIIb/IIIa Inhibition with Eptifibatide or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (Heidelberg; Tuebingen; Kirchheim; Solingen, Germany)

- Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilamentdirected Agents in Tumor Model Systems In Vivo. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (Syracuse, NY, USA)

- A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (Columbus, OH; San Juan Capistrano, CA, USA)


- Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (Jackson, MS, USA)

- Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKESFELDT, J. ROSENBERG, I. GÖGENUR (Køge; Copenhagen; Herlev, Denmark)

- The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOISKI, D. SAIJUTHI, A. SCHAPIRO, A. GJEDDE, J. HAU (Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC; Canada)

- No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (Tokyo; Saitama; Aichi, Japan)

- Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUIKIKAWA, A. TANAKA (Kobe; Osaka; Saita; Kanan, Japan)


FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Instructions to Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNxxxxxxxx (where xxxxxxxx represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTxxxxxxxx (where xxxxxxxx represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (Beijing, China; Cardiff, UK)


Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (Boca Raton, FL, USA)


Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia)


Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANJSKI, C. WROBEL, M. SCHRAMM (Düsseldorf, Germany)


Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (Bucharest, Romania; Charlestown, MA, USA)
Treatment of Multiple Unresectable Basal Cell Carcinomas from Gorlin-Goltz Syndrome: A Case Report. F.O. OJEVWE, C.D. OJEVWE, J.P. ZACNY, A.Z. DUDEK, A. LIN, P. KOHLITZ (Syracuse, NY; Chicago, IL, USA) ........................................................................................................................................... 1777


Lack of Difference in Acute Nephrotoxicity of Intravenous Bisphosphonates Zoledronic Acid and Ibandronate in Women with Breast Cancer and Bone Metastases. D.W. LUEDDERS, J. STEINHOFF, M. THILL, A. RODY, M.K. BOHLMANN (Oldenburg; Luebeck; Frankfurt, Germany) ........................................................................................................ 1797

Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib. C. GODIN, C. LOUANDRE, S. BODEAU, M. DIOUF, Z. SAIDAK, M.-A. CONTE, B. CHAUFFERT, J.-C. BARBARE, N. BARGET, J.-C. TRINCHET, N. GANNE, A. GALMICHE (Amiens; Bondy; Bobigny; Paris, France) ........................................................................................................ 1803


Safety and Efficacy of Adjuvant Therapy with Oxaliplatin, Leucovorin and 5-Fluorouracil After Mesorectal Excision with Lateral Pelvic Lymph Node Dissection for Stage III Lower Rectal Cancer. S. IWASA, H. SOUDA, K. YAMAZAKI, D. TAKAHARI, Y. MIYAMOTO, Y. TAKII, S. IKEDA, T. HAMAGUCHI, Y. KANEMITSU, Y. SHIMADA (Tokyo; Chiba; Shizuoka; Aichi; Kumamoto; Niigata; Hiroshima, Japan) ........................................................................................................ 1815

Book Reviews ................................................................................................................................ 1821

Announcements ................................................................................................................................ 1833
Circulating Hepatocyte Growth Factor is Correlated with Resistance to Cetuximab in Metastatic Colorectal Cancer. K. YONESAKA, T. SATOH, S. UEDA, T. YOSHIDA, M. TAKEDA, T. SHIMIZU, I. OKAMOTO, K. NISHIO, T. TAMURA, K. NAKAGAWA (Osaka; Fukuoka, Japan) .................................................. 1683

Surgical Loupes at 5.0× Magnification and the VIO Soft-coagulation System Can Prevent Postoperative Pancreatic Fistula in Duct-to-Mucosa Pancreaticojejunostomy. Y.-I. YAMASHITA, Y. YOSHIDA, T. KURIHARA, E. TSUJITA, K. TAKEISHI, T. ISHIDA, T. IKEDA, Y. FURUKAWA, K. SHIRABE, Y. MAEHARA (Fukuoka; Hiroshima, Japan) .......................................................................................... 1691

Vinorelbine and Cisplatin in Patients with Advanced Non-small Cell Lung Cancer with Interstitial Pneumonia. N. WATANABE, S. NIHO, K. KIRITA, S. UMEMURA, S. MATSUMOTO, K. YOH, H. OHMATSU, K. GOTO (Kashiwa, Japan) .......................................................................................... 1697


Primary Malignant Melanoma of the Breast: Case Report and Review of the Literature. D. DRUEPPEL, B. SCHULTHEIS, W. SOLASS, H. ERGONENC, C.B. TEMPFER (Herne; Bochum, Germany) .................. 1709

Cyclin A Correlates with YB1, Progression and Resistance to Chemotherapy in Human Epithelial Ovarian Cancer. M. CYBULSKI, B. JAROSZ, A. NOWAKOWSKI, W. JELENIEWSKA, E. KUTARSKA, W. BEDNAREK, A. STEPULAK (Lublin; Warsaw, Poland) .................................................................... 1715

Clinical Outcomes of Patients with Localized and Locally Advanced Prostate Cancer Undergoing High-dose-rate Brachytherapy with External-beam Radiotherapy at our Institute. T. MAKINO, A. MIZOKAMI, M. NAMIKI (Kanazawa, Ishikawa, Japan) ............................................................................................ 1723


Prognostic Factor of Severe Complications in Patients with Hypopharyngeal Cancer with Primary Concurrent Chemoradiotherapy. L.-Y. CHEN, C.-C. HUANG, Y.-A. TSOU, D.-T. BAU, M.-H. TSAI (Taichung, Taiwan, ROC) ..................................................................................................................... 1735

The Effect of Re-operation on Survival in Patients with Recurrent Glioblastoma. E. FRANCESCHI, M. BARTOLOTTI, A. TOSONI, S. BARTOLINI, C. STURIALE, A. FIORAVANTI, E. POZZATI, R. GALZIO, A. TALACCHI, L. VOLPIN, L. MORANDI, D. DANIELI, M. ERMANI, A.A. BRANDES (Bologna; L’Aquila; Verona; Vicenza; Padova, Italy) ................................................................. 1743


The Impact of Radiotherapy on Symptoms, Anxiety and QoL in Patients with Cancer. P. GOGOU, E. TSILDA, E. PARPA, I. KOUVARIS, D. DAMIGOS, M. BALAFOUTA, V. MAUREAS, K. MYSTAKIDOU (Ioannina; Athens, Greece) ........................................................................................................... 1771

Contents continued on the preceding page

Efficacy of Tegafur-Uracil in Advanced Urothelial Cancer Patients after the Treatment Failure of Platinum-based Chemotherapy. A. MAOLAKE, K. IZUMI, R. TAKAHASHI, S. ITAI, K. MACHIOKA, H. YAEGASHI, T. NOHARA, Y. KITAGAWA, Y. KADONO, H. KONAKA, A. MIZOKAMI, M. NAMIKI (Ishikawa, Japan) ..............................................................

A Case of Endobronchial NUT Midline Carcinoma with Intraluminal Growth. S. WATANABE, S. HIRANO, S. MINE, A. YOSHIDA, T. MOTOI, S. ISHII, G. NAKA, Y. TAKEDA, T. IGARI, H. SUGIYAMA, N. KOBAYASHI (Tokyo, Japan) ...........................................................................

Pancreatoduodenectomy En Bloc with Portal and Superior Mesenteric Artery Resection – A Case Report and Literature Review. V. BRASOVEANU, C. ANGHEL, I. BARBU, M. PAUTOV, M.I. IONESCU, M. MOTTHOR, I. BALESCU, S. DIMA, N. BACALBASA (Bucharest, Romania) ....................................

Long-term Platinum Retention After Platinum-based Chemotherapy in Testicular Cancer Survivors: A 20-Year Follow-up Study. L.V. HJELLE, P.O.M. GUNDERSEN, J. OLDBJØRNE, M. BRYDØY, T. TANDSTAD, T. WILSGAARD, S.D. FOSSÅ, R.M. BREMNES, H.S. HAUrones (Trondheim; Bergen; Oslo, Norway)..............................................................................................................

Emotional Personality/Proximity Versus Emotional Authenticity in Patient–Physician Communication in Healthy Study Participants, and in Patients with Benign Breast Disease, and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELENIN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland) .......

The Impact of Thyroid Nodule Size on the Risk of Malignancy in Follicular Neoplasms. Y. IBRAHIM, S.E.H. MOHAMED, A. DENIWAR, Z.H. AL-QURAYSHI, A.N. KHAN, K. MOROZ, P. FRIEDLANDER, E. KANDIL (New Orleans, LA, USA) ........................................................................................................

Aberrant P53 Expression Lacks Prognostic or Predictive Significance in Colorectal Cancer: Results from the VICTOR Trial. M.J. MCGREGOR, W. FADHIL, R. WHARTON, Y. YANAGISHI, M. PRESZ, A. PRITCHARD, C. WOMACK, S. DUTTON, R.S. KERR, D.J. KERR, E.C. JOHNSTONE, M. ILYAS (Oxford; Nottingham; Macclesfield, Cheshire, UK) ........................................................................................................


EBV, HSV, CMV and HPV in Laryngeal and Oropharyngeal Carcinoma in Polish Patients. D. POLZ GRUSZKA, A. STEC, J. DWORZAŃSKI, M. POLZ DACEWICZ (Lublin, Poland) ..........................................................


Validity of Sentinel Lymph Node Biopsy by ICG Fluorescence for Early Head and Neck Cancer. T. NAKAMURA, Y. KOGASHIWA, H. NAGAFUJI, K. YAMAUCHI, N. KOHNO (Tokyo, Japan) ..................

Operation for Preservation of Lung Parenchyma in Central Lung Cancer–In Vivo and Ex Situ Reimplantation Techniques. C. EMMANOULIDES, S. TRYFON, S. BAKA, H. TITOPoulos, A. DAGER, D. FILIPPOU (Thessaloniki, Greece) ........................................................................................................
Anticancer Effect of a Novel Palladium–Saccharinate Complex of Terpyridine by Inducing Apoptosis on Ehrlich Ascites Carcinoma (EAC) in Balb-C Mice. E.I. IKITIMUR-ARMUTAK, K. SONMEZ, K. AKGUN-DAR, G. SENNAZLI, A. KAPUCU, F. YIGIT, V.T. YILMAZ, E. ULUKAYA (Istanbul; Bursa, Turkey) ................................................................. 1491

Supernatants of Tumours Treated with Chemotherapy Can Alter Tumour Growth and Development In Vivo. W.M. LIU, K.A. SCOTT, A.G. DALGLEISH (London, UK) ......................................................... 1499

Elimination of Ras Suppressor-1 from Hepatocellular Carcinoma Cells Hinders their In Vitro Metastatic Properties. V. GKRETSI, D.P. BOGDANOS (Larissa, Greece; London, UK) ........................................... 1509

Expression of Immunohistochemical Markers of Progression in Pre-cancerous and Cancerous Human Colon: Correlation with Serum Vitamin D Levels. A. JUNIKU-SHKOLLLI, S. MANXHUKA-KERLIU, H. AHMETAJ, V. KHARE, S. ZEKAI (Prishtina, Republic of Kosovo; Vienna, Austria) ................................................................. 1513

APOBEC3B: A Potential Factor Suppressing Growth of Human Hepatocellular Carcinoma Cells. P.-F. WU, Y.-S. CHEN, T.-Y. KUO, H.-H. LIN, C.-W. LIU, L.-C. CHANG (Kaohsiung, Taiwan, ROC) ...................................................... 1521

Predominance of Th17 Over Regulatory T-Cells in Pleural Effusions of Patients with Lung Cancer Implicates A Proinflammatory Profile. H. PRADO-GARCIA, S. ROMERO-GARCIA, U. RUMBO-NAVA, J.S. LOPEZ-GONZALEZ (Mexico City, Mexico) ........................................................................................................ 1529


In Vitro Exposure of NK-92 Cells to Serum from Patients with Non-small Cell Lung Cancer Impairs Their Cytotoxicity. D. TSARTSALIS, D. GRAPSA, M. SKOPELITI, E. DRAGIOTI, A. CHARPIDOU, E. POLITI, O. TSITSILONIS, K. SYRIGOS (Athens, Greece) ................................................................. 1543

Clinical Studies


The Concurrent Use of Aromatase Inhibitors and Radiotherapy Induces Echocardiographic Changes in Patients with Breast Cancer. T. SKYTTÅ, S. TUOHINEN, V. VIRTANEN, P. RAATIKAINEN, P.-L. KELLOKUMPU-LEHTINEN (Tampere, Finland) ........................................................................................................ 1559

Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer. J.R. HECHT, T.R. REID, C.R. GARRETT, J.T. BECK, S.J. DAVIDSON, M.J. MACKENZIE, U. BRANDT, S. RIZVI, S. SHARMA (Santa Monica; La Jolla; Northridge, CA; Houston, TX; Fayetteville, AR; East Hanover, NJ; Salt Lake City, UT, USA; London, ON, Canada; Basel, Switzerland) .......................................................... 1567

Matched-pair Analysis of Dendritic Cell Versus Targeted-therapy in Patients with Metastatic Renal Cell Carcinoma. A. ISAAK, S. HAUSER, S. ROGENHOFER, I.G.H. SCHMIDT-WOLF (Bonn, Germany) .... 1575

Hybrid-including Endoscopic versus Open Hepatic Resection for Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: A Propensity Case-matched Analysis. T. BEPPU, H. HAYASHI, H. OKABE, K. IMAI, H. NITTA, T. MASUDA, D. HASHIMOTO, A. CHIKAMOTO, T. ISHIKO, K. KIKUCHI, H. Baba (Kumamoto, Japan) ........................................................................................................ 1583

Contents continued on the preceding page
PCK3145 Inhibits Proliferation and Induces Apoptosis in Breast and Colon Cancer Cells. A. KOSTOPOULOS, E. PAPAGEORGIOU, M. KOUTSILIERIS, G. SIVOLAPENKO (Patras; Athens, Greece) ............................................. 1377


miR-200a, miR-200b and miR-429 Are Onco-miRs that Target the PTEN Gene in Endometrioid Endometrial Carcinoma. K. YONEYAMA, O. ISHIBASHI, R. KAWASE, K. KUROSE, T. TAKESHITA (Tokyo; Sakai, Japan) .......................................................... 1401

Aberrant Methylation of GCNT2 Is Tightly Related to Lymph Node Metastasis of Primary CRC. K. NAKAMURA, K. YAMASHITA, H. SAWAKI, M. WARAYA, H. KATOH, N. NAKAYAMA, H. KAWAMATA, H. NISHIMIYA, A. EMA, H. NARIMATSU, M. WATANABE (Kanagawa; Ibaraki, Japan) ........................................................................................................ 1411


β-catenin Helices in the Cytoplasm of Sporadic and FAP Duodenal Adenomas. C.A. RUBIO, A. KAUFELDT, R. KOHAN, M. USHOIDA, E. EZELIUS, S. BJÖRK, J. LINDAHL (Stockholm, Sweden) ................................................. 1433

Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts. M. NUKATSUKA, F. NAKAGAWA, H. SAITO, M. SAKATA, J. UCHIDA, T. TAKECHI (Tokushima, Japan) .............................................................................................................. 1437

MicroRNA-503 Promotes Tumor Progression and Acts as a Novel Biomarker for Prognosis in Oesophageal Cancer. S. IDE, Y. TOIYAMA, T. SHIMURA, M. KAWAMURA, H. YASUDA, S. SAIGUSA, M. OHI, K. TANAKA, Y. MOHRI, M. KUSUNOKI (Tsukushima, Japan) .............................................................. 1447


Phosphatidylserine-specific Phospholipase A1 (PS-PLA1) Expression in Colorectal Cancer Correlates with Tumor Invasion and Hematogenous Metastasis. Y. IIDA, E. SUNAMI, H. YAMASHITA, M. HIYOSHI, S. ISHIHARA, H. YAMAGUCHI, A. INOUE, K. MAKIDE, N.H. TSUNO, J. AOKI, J. KITAYAMA, T. WATANABE (Tokyo; Miyagi, Japan) .............................................................. 1459


Sulfobetaine (Dimethylsulfoniopropionate) and Glycine Betaine Show Incompatible Involvement in Crucial Ehrlich Ascites Carcinoma in Mice. K. NAKAJIMA, Y. NAKAJIMA, S. TSUIIWAKI (Hyogo; Okayama, Japan) ............... 1475

Chemotherapy-induced Changes and Immunosenescence of CD8+ T-Cells in Patients with Breast Cancer. O.O. ONYEMA, L. DECOSTER, R. NJEMINI, L. N. FORTI, I. BAUTMANS, M. DE WAELE, T. METS (Brussels, Belgium) ...................................................................................... 1481

Contents continued on the preceding page
MicroRNA Expression in Differentially Metastasizing Tumors of the Head and Neck: Adenoid Cystic Versus Squamous Cell Carcinoma. J.A. VEIT, K. SCHECKENBACH, P.J. SCHULER, S. LABAN, S.P. WIGGENHAUSER, J. THIERAUF, J.P. KLUSSMANN, T.K. HOFFMANN (Ulm; Düsseldorf; Giessen, Germany) ................................................................. 1271

Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mTOR Pathways. S. JAVAID, K. TERAI, A.Z. DUDEK (Minneapolis, MN; Chicago, IL, USA) ............................... 1279

Remodeling of Tannic Acid Crosslinked Collagen Type I Induces Apoptosis in ER+ Breast Cancer Cells. T.A. NGOBILI, H. SHAH, J.P. PARK, K.W. KWIST, B. INSKEEP, K.J.L. BURG, B.W. BOOTH (Clemson, SC; Manhattan, KS, USA) ............................................ 1285

Ectopic Expression of Protein Kinase C-β Sensitizes Head and Neck Squamous Cell Carcinoma to Diterpene Esters. R.A. ADAMS, M.M.A. D’SOUZA, C.J. PIERCE, N. KORICA, B. WALLWORK, P.G. PARSONS, B. PANIZZA, G.M. BOYLE (Brisbane, Queensland, Australia) .......................................................... 1291


The Protective Effect of Pyrimidine Nucleosides on Human HaCaT Keratinocytes Treated with 5-FU. J. HARTINGER, P. VESELÝ, I. NETÍKOVÁ, E. MATOUŠKOVÁ, L. PETRUŽELKA (Prague; Brno, Czech Republic) .......................................................... 1303

Effect of Anaesthetic Technique on Immune Cell Infiltration in Breast Cancer: A Follow-up Pilot Analysis of a Prospective, Randomised, Investigator-masked Study. F. DESMOND, J. MCCORMACK, N. MULLIGAN, M. STOKES, D.J. BUGGY (Dublin, Ireland; Cleveland, OH, USA) ....................................................... 1311


DNA Damage in Dihydroartemisinin-resistant Molt-4 Cells. J. PARK, H.C. LAI, T. SASAKI, N.P. SINGH (Seattle, WA, USA) .............................................................. 1339


HVEM Expression Contributes to Tumor Progression and Prognosis in Human Colorectal Cancer. T. INOUE, M. SHO, S. YASUDA, S. NISHIWADA, S. NAKAMURA, T. UEDA, N. NISHIGORI, K. KAWASAKI, S. OBARA, T. NAKAMOTO, F. KOYAMA, H. FUJIY, Y. NAKAJIMA (Kashihara, Nara, Japan) .... ........................................ 1359

Flunarizine Exhibits In Vitro Efficacy Against Lymphoma and Multiple Myeloma Cells. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, S. BLAUM-FEDER, T. ENDO, I.G.H. SCHMIDT-WOLF (Bonn, Germany; Sapporo, Japan) .......................................................... 1369